Longevity for Investors with Dr. Greg Bailey and Jess Larsen How Could a New Longevity Medicine Create $200B Per Year in Revenue? Dr. Greg Bailey and I asked top VC Alex Colville from age1
Jul 5, 2024
In this discussion, venture investor Alex Colville, co-founder of age1, shares his journey from an early interest in longevity to deploying over $100 million into biotech startups. He emphasizes the significance of founder-market fit and the unexpected scalability of small investments. The conversation turns to the potential of the first longevity-approved drug, which could generate up to $200 billion annually. Alex also explores the exciting world of synthetic embryos and the bold risks necessary for early-stage investments.
AI Snips
Chapters
Transcript
Episode notes
Early Passion Led To Deep Longevity Experience
- Alex Colville traced his longevity passion to an eight-year-old moment growing up in Maine and later worked in David Sinclair's lab and Tom Rando's lab.
- He helped run three family offices and deployed about $100M into longevity before joining Laura Deming to build Age1.
Back Founders Early But Demand Commerciality
- Investors can make outsized impact with relatively small checks by backing founders early and giving them confidence.
- Prioritize for-profit returns so companies can attract later-stage capital needed for expensive biotech development.
Dog Longevity Became A Scalable Business
- Loyal (dog longevity) began when founder Celine incubated the idea with Laura Deming and turned veterinary longevity into a fundable business.
- Loyal raised over $60M, secured FDA early efficacy guidance, and scaled from a small initial check to major rounds.